[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-360496-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-360496-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prognostic-value-of-cachexia-index-in-hr-her2-metastatic-breast-cancer-treated-with-cdk46-inhibitors","Prognostic value of cachexia index in HR +/HER2 − metastatic breast cancer treated with CDK4/6 inhibitors","","Purpose The prognostic significance of body composition parameters in HR +/HER2 − metastatic breast cancer patients receiving CDK4/6 inhibitors remains insufficiently defined. The cachexia index (CXI), combining skeletal muscle mass, nutritional status, and systemic inflammation, may offer additional prognostic insight. This study assessed whether body composition measures, especially CXI, predict outcomes in this clinical setting. Methods used retrospective L3 imaging assessment and Cox regression. Results showed high CXI independently predicted improved PFS and OS. Conclusion CXI can support risk classification and multidisciplinary supportive care.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prognostic-value-of-cachexia-index-in-hr-her2-metastatic-breast-cancer-treated-with-cdk46-inhibitors/360496/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prognostic-value-of-cachexia-index-in-hr-her2-metastatic-breast-cancer-treated-with-cdk46-inhibitors/360496.png","ImageObject",300,407,{"name":42,"@type":43},"Grenda","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does the cachexia index (CXI) represent in this study?","Question",{"text":63,"@type":64},"CXI is a composite marker integrating skeletal muscle mass, nutritional status, and systemic inflammation. It is calculated using skeletal muscle index, serum albumin, and the neutrophil-to-lymphocyte ratio.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were sarcopenia and body composition parameters assessed?",{"text":68,"@type":64},"Body composition was evaluated using baseline imaging at the L3 vertebral level. Sarcopenia was defined by skeletal muscle index (SMI) \u003C 38.5 cm2/m2.",{"name":70,"@type":61,"acceptedAnswer":71},"What was the key prognostic finding regarding CXI?",{"text":72,"@type":64},"High CXI (≥ 44.9) was associated with significantly longer PFS and OS. In multivariate Cox analysis, high CXI independently predicted reduced risk of disease progression and death.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},360496,1790816632,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":113,"preview_page_count":33,"preview_urls":145},7971474921005,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Keskin et al. BMC Cancer (2026) 26:741 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-16078-z](https://doi.org/10.1186/s12885-026-16078-z)  \nRESEARCH Open Access  \nPrognostic value of cachexia index in HR +/ HER2 − metastatic breast cancer treated with CDK4/6 inhibitors  \nGul Sema Yildiran Keskin 1*, Gulsah Gedikli Turgut2, Gizem Yildirim1, Esmanur Kaplan Tuzun1, Volkan Aslan1, Musa Baris Aykan1, Semra Ince2 and Nuri Karadurmus 1  \nAbstract  \nPurpose The prognostic significance of body composition parameters in patients with HR + /HER2 − metastatic breast cancer treated with CDK4/6 inhibitors remains poorly defined. The cachexia index (CXI), a composite marker integrating skeletal muscle mass, nutritional status, and systemic inflammation, may provide additional prognostic information in this setting. This study aimed to evaluate the prognostic value of body composition parameters, with a particular focus on CXI, in this patient population.  \nMethods This retrospective single-center study included 84 patients with HR + /HER2 − metastatic breast cancer receiving CDK4/6 inhibitor therapy. Body composition parameters were assessed using baseline imaging at the L3 vertebral level. Sarcopenia was defined as skeletal muscle index (SMI) \u003C 38.5 cm2/m2. CXI was calculated as [skeletal muscle index × serum albumin]/neutrophil-to-lymphocyte ratio. Prognostic factors were evaluated using univariate and multivariate Cox regression analyses.  \nResults At a median follow-up of 42.0 months, median PFS and OS were 40.8 and 49.6 months, respectively. The median SMI was 32.1 cm2/m2 (IQR 25 .2–39. 9) . Sarcopenia was present in 50 patients (64 . 3%) . Patients with high  \nCXI (≥ 44 . 9) demonstrated significantly longer PFS (not reached vs. 26.3 months, p = 0 . 001) and OS (not reached vs. 33.3 months, p = 0 . 004) compared to those with low CXI. In multivariate analysis, high CXI independently predicted reduced risk of disease progression (HR 0 . 34, 95% CI 0 .16–0. 71, p = 0 . 004) and death (HR 0 . 26, 95% CI 0.11–0. 61,  \np = 0 . 002) . While sarcopenia and low skeletal muscle density were associated with inferior outcomes in univariate analysis, only CXI retained independent prognostic significance after adjustment for confounding factors including liver metastases and luminal subtype.  \nConclusion In this study, we demonstrated that CXI serves as an independent prognostic biomarker for both PFSand OS in patients with HR + /HER2 − metastatic breast cancer treated with CDK4/6 inhibitors. CXI, a cost-effective tool that can be easily obtained from routine imaging and laboratory parameters, has the clinical capacity to facilitate risk classification and guide the multidisciplinary supportive interventions.  \n*Correspondence:  \nGul Sema Yildiran Keskin[gulsemayildiran@gmail.com](gulsemayildiran@gmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses","cbCaisSU1RyKRk9B","https://ap.wps.com/l/cbCaisSU1RyKRk9B","pdf",1835262,12,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What does the cachexia index (CXI) represent in this study?\",\"answer\":\"CXI is a composite marker integrating skeletal muscle mass, nutritional status, and systemic inflammation. It is calculated using skeletal muscle index, serum albumin, and the neutrophil-to-lymphocyte ratio.\"},{\"question\":\"How were sarcopenia and body composition parameters assessed?\",\"answer\":\"Body composition was evaluated using baseline imaging at the L3 vertebral level. Sarcopenia was defined by skeletal muscle index (SMI) \\u003c 38.5 cm2/m2.\"},{\"question\":\"What was the key prognostic finding regarding CXI?\",\"answer\":\"High CXI (≥ 44.9) was associated with significantly longer PFS and OS. In multivariate Cox analysis, high CXI independently predicted reduced risk of disease progression and death.\"}]","Prognostic value of cachexia index in HR +/HER2 − metastatic breast cancer treated with CDK4/6 inhibitors | PDF",1790140271,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85d5688565073bbdaf097b892513401c.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1cdfdd3a8c05bf1c92cc79352de99b16.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0de88afa14d329c9759027b85cf59ca2.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/27bfd8fe3958c6262d4f315b841d3b32.webp",980,1306]